Highlights
1. Single-cell transcriptomics of colorectal cancer tumour-draining lymph nodes identified a distinct immunosuppressive niche enriched for SPP1+ macrophages and differentiating regulatory T cells.
2. The study proposes a mechanistic axis in which SPP1 signals through CD44 to activate NF-κB1, promoting maturation of CD137+ regulatory T cells.
3. In preclinical models, dual blockade with LNP-siSPP1 and anti-CD44 monoclonal antibody reduced lymph node metastasis and improved CD8+ T-cell function.
4. The work suggests that tumour-draining lymph nodes are not passive reservoirs of metastasis but active immune-educating sites that may be therapeutically targetable.
Clinical Background and Unmet Need
Colorectal cancer remains a major global cause of cancer morbidity and mortality, and lymph node involvement is a key determinant of staging, prognosis, and treatment planning. Tumour-draining lymph nodes are not simply anatomical conduits for dissemination; they are immune-active microenvironments where tumour antigens, myeloid cells, T cells, and stromal elements interact. This makes them important both for understanding metastasis and for identifying nodes of immune escape that may limit the effectiveness of therapy.
Despite progress in systemic therapy and immune checkpoint blockade, most patients with microsatellite stable colorectal cancer derive limited benefit from current immunotherapies. One reason is that immune suppression is established early and in multiple compartments, including the tumour itself and the lymphatic drainage basin. Regulatory T cells (Tregs), which restrain immune activation and maintain self-tolerance, can be co-opted by tumours to suppress anti-tumour responses. A better understanding of how Tregs are generated or expanded within tumour-draining lymph nodes may therefore reveal new therapeutic vulnerabilities.
Study Design and Methods
Wang and colleagues used single-cell RNA sequencing on 23 quadruplet-matched samples from seven colorectal cancer patients, including primary tumours, adjacent normal tissues, tumour-free lymph nodes (TFLN), and tumour-invaded lymph nodes (TILN). This paired design is a major strength because it allows comparison within the same patient across tumour-adjacent and lymphatic compartments, reducing inter-individual biological noise.
The investigators then pursued a multi-layer validation strategy. Mechanistic findings were tested with in vitro functional assays, CRISPR knockout in primary Tregs, and in vivo murine footpad-popliteal lymph node metastasis models. They further evaluated lipid nanoparticle-encapsulated siSPP1 (LNP-siSPP1), anti-CD44 monoclonal antibody therapy, and combined treatment. Finally, they integrated multiomics analyses from independent colorectal cancer cohorts to assess reproducibility and clinical relevance.
Because the abstract does not provide detailed effect sizes, confidence intervals, or full statistical parameters, interpretation should focus on the direction, consistency, and biological coherence of the results rather than overclaiming quantitative precision.
Main Findings
The central observation was that TILNs displayed a distinct immune landscape compared with TFLNs, characterized by expansion of SPP1+ macrophages and active niches supporting Treg differentiation. In other words, lymph nodes invaded by tumour were not merely colonized by cancer cells; they were immunologically remodeled into sites that appeared to favor immune suppression and maturation of Tregs into a more suppressive phenotype.
SPP1, also known as osteopontin, is a pleiotropic cytokine-like protein linked to inflammation, fibrosis, tissue remodeling, and cancer progression. In this study, SPP1+ macrophages were identified as the dominant myeloid population associated with the TILN immunosuppressive environment. These macrophages were implicated in driving Treg differentiation toward CD137+ subsets. CD137, also known as TNFRSF9, is a costimulatory receptor often associated with activated immune states; however, in this context, the CD137+ Treg subset was functionally immunosuppressive, highlighting that phenotypic activation and anti-tumour activity are not always aligned.
Mechanistically, the authors reported that SPP1 acted through CD44, a broadly expressed cell-surface receptor involved in cell adhesion, migration, and signaling. Engagement of CD44 appeared to activate NF-κB1, which directly bound the promoter of TNFRSF9, thereby promoting transcriptional programs linked to CD137+ Treg maturation. This SPP1-CD44-NF-κB1-TNFRSF9 pathway provides a plausible molecular bridge between macrophage-derived signals and Treg phenotype remodeling.
Functional validation supported the importance of this axis. In vitro assays and CRISPR knockout experiments in primary Tregs helped confirm that the signaling pathway was not simply correlative. The in vivo data were particularly notable: LNP-siSPP1 plus anti-CD44 monoclonal antibody synergistically suppressed lymph node metastasis, reduced the abundance of CD137+ Tregs, and improved CD8+ T-cell function. Restoration of CD8+ T-cell activity is clinically important because cytotoxic T cells are central effectors of anti-tumour immunity and are frequently disabled in suppressive microenvironments.
The consistency of findings across preclinical models and patient-derived datasets strengthens confidence in the biological relevance of the proposed mechanism. Still, the therapeutic implications remain preliminary until tested in human trials.
Interpretation for Clinicians
This study advances a useful concept: lymph nodes involved in colorectal cancer metastasis may actively educate the immune system toward tolerance, not just provide a route for spread. If SPP1+ macrophages are central organizers of that process, they could serve as both biomarkers and intervention points. The work also reinforces the idea that effective immunotherapy may require combination strategies aimed not only at tumour cells but also at immune-conditioning compartments such as tumour-draining lymph nodes.
From a translational perspective, the dual-targeting approach is intriguing. Inhibiting SPP1 production and blocking CD44-mediated signal transduction could theoretically dismantle the macrophage-to-Treg communication loop. However, CD44 is widely expressed, and SPP1 participates in normal tissue repair and immune regulation. These factors raise potential concerns about specificity, toxicity, and unintended effects on host defense or wound healing. Such risks will require careful study before any clinical application.
Expert Commentary and Limitations
The study’s strengths include a paired human sample design, single-cell resolution, mechanistic validation, and cross-model reproducibility. This integrated workflow makes the conclusion more compelling than a purely descriptive transcriptomic study. The focus on tumour-draining lymph nodes is also timely, as nodal immunity is often underappreciated relative to the primary tumour microenvironment.
Nonetheless, several limitations should temper interpretation. First, the human discovery cohort was small, involving seven patients. While single-cell methods can generate rich biological insights from limited samples, small cohorts may not capture the heterogeneity of colorectal cancer across molecular subtypes, anatomical sites, stages, or treatment histories. Second, the abstract does not report detailed clinical outcomes, hazard ratios, or independent prospective validation in larger patient cohorts. Third, murine footpad-popliteal metastasis models are useful for mechanistic testing but may not fully recapitulate the complexity of human colorectal lymphatic spread. Fourth, the therapeutic platform, LNP-siSPP1, is promising but still preclinical; delivery efficiency, off-target effects, dosing, and immunogenicity remain key translational questions.
Another important nuance is that CD137 is usually discussed as a stimulatory molecule in T cells and as a target in immunotherapy research. Its association with an immunosuppressive Treg subset in this setting underscores the context dependence of immune markers. Clinicians and researchers should therefore be cautious about assuming a single functional meaning for any immune phenotype without spatial and cellular context.
Clinical and Research Implications
If confirmed in larger datasets, the SPP1-CD44-NF-κB1 axis could inform several translational applications. It may help stratify patients with nodal immune suppression, guide biomarker development for metastatic risk, and support combination immunotherapy strategies in colorectal cancer. The work also suggests that successful immune reprogramming may require targeting the lymph node niche itself, not solely the primary tumour.
Future research should address whether this pathway is enriched in specific colorectal cancer subsets, whether it correlates with microsatellite status, nodal burden, or survival, and whether it is modifiable with agents that are clinically feasible. It will also be important to determine whether SPP1+ macrophages are causal drivers of metastasis or part of a broader suppressive ecosystem that includes fibroblasts, dendritic cells, and endothelial cells.
Conclusion
Wang and colleagues provide compelling mechanistic evidence that SPP1+ macrophages promote the differentiation and maturation of suppressive CD137+ Tregs in colorectal cancer tumour-draining lymph nodes through an SPP1-CD44-NF-κB1 signaling pathway. By linking nodal immune remodeling to metastatic progression, the study identifies a plausible therapeutic target and broadens the conceptual framework for colorectal cancer immunotherapy. The findings are strong and biologically coherent, but they remain preclinical and require larger clinical validation before practice can change.
References
1. Wang J, Zhou M, Tan B, Shi H, Liu L, Xu X, Ge X, Yang G, Sheng B, He X, Li J, Wu J. SPP1+ macrophages facilitate the differentiation and maturation of regulatory T cells in tumour-draining lymph nodes of colorectal cancer. Gut. 2026-06-12. PMID: 42285754.
2. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49.
3. Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024.
4. Belli C, Duso BA, Ferraro E, et al. Immune checkpoint inhibitors in metastatic colorectal cancer: current status and future perspectives. Cancer Treat Rev. 2021;97:102204.
5. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298-306.
6. Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5(1):3-8.
7. Tang H, Qiao J, Fu YX. Immunotherapy and tumor microenvironment in colorectal cancer. Cancer Lett. 2022;530:27-39.